Granite Point Capital Management’s Ovid Therapeutics OVID Stock Holding History

Granite Point Capital Management’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-348,263	Closed	-$1.45M	–	93
2019 Q4	$1.45M	Hold	348,263	–	–	0.23%	47
2019 Q3	$1.13M	Sell	348,263 -69,594	-17%	-$158K	0.18%	41
2019 Q2	$773K	Hold	417,857	–	–	0.05%	68
2019 Q1	$740K	Buy	+417,857	New	+$1.04M	0.07%	78
2018 Q4	–	Sell	-111,826	Closed	-$634K	–	117
2018 Q3	$634K	Sell	111,826 -167,214	-60%	-$1.27M	0.04%	93
2018 Q2	$2.18M	Buy	279,040 +266,840	+2,187%	+$2.29M	0.2%	46
2018 Q1	$86K	Sell	12,200 -2,800	-19%	-$22.7K	0.01%	106
2017 Q4	$148K	Buy	+15,000	New	+$138K	0.01%	94

Other funds holding OVID

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Granite Point Capital Management's OVID Position: Q1 2020 in Review

Granite Point Capital Management sold out of Ovid Therapeutics (OVID) in Q1 2020, closing a stake of 348,263 shares — an estimated $1.45M sold.

Granite Point Capital Management first reported a position in OVID in Q4 2017 and held it in 8 quarters. The position peaked at $2.18M in Q2 2018. 57 funds tracked by Wall St. Rank hold OVID as of Q1 2020.

Granite Point Capital Management reported no remaining Ovid Therapeutics position as of Q1 2020 after selling out during the quarter.
Granite Point Capital Management sold 348,263 Ovid Therapeutics shares in Q1 2020, an estimated $1.45M.
Granite Point Capital Management first reported a position in Ovid Therapeutics in Q4 2017 and held it in 8 quarters.
Granite Point Capital Management's Ovid Therapeutics position peaked at $2.18M in Q2 2018.
57 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2020.

Based on Granite Point Capital Management's 13F filing for Q1 2020, filed 12 May 2020.